Garratty G
Crit Rev Clin Lab Sci. 1984;20(1):25-56. doi: 10.3109/10408368409165769.
In vitro detection of red cell-bound complement can be important in the differential diagnosis of autoimmune and drug-induced immune hemolytic anemias; it can also be a sensitive test for the detection of complement-binding alloantibodies, e.g., in compatibility testing. Red cell-bound complement can be detected by the antiglobulin test if suitable antiglobulin sera (AGS) are utilized. In 1971, the Federal Standards for AGS were criticized because so-called broad spectrum AGS used routinely in blood banks were shown to often be deficient in anticomplement reactivity. In the new few years commercial regents changed with regard to the quantity and specificity of their anticomplement components. A great deal of controversy developed as to the true importance of detecting red cell-bound complement, the particular fragments of complement that should be detected, and the causes of nonspecific reactions that seemed to be occurring, especially with the increasing usage of new techniques utilizing low ionic strength media. When monospecific anti-IgG and anti-C3 became available commercially, the controversy regarding diagnostic testing was resolved as direct antiglobulin testing could be performed with these reagents rather than the broad spectrum reagents. Two main questions remained: how rare are alloantibodies that are only detectable by the anticomplement component of AGS? How clinically significant are such antibodies? The results of our 3-year study indicated that such antibodies (usually anti-Kidd) occurred with a incidence of 1/8000 sera tested. Some of these antibodies seemed capable of shortening the life span of transfused red cells, as determined by 51Cr survival studies; some showed negligible cell destruction. Severe transfusion reactions due to such antibodies would seem unlikely. Individual laboratories will have to balance the risk of missing some complement-dependent antibodies of possible clinical significance with the increased nonspecificity encountered in their own laboratory with AGS containing anticomplement.
体外检测红细胞结合补体在自身免疫性和药物性免疫性溶血性贫血的鉴别诊断中可能具有重要意义;在检测补体结合同种抗体时,如在交叉配血试验中,它也可以是一种敏感的检测方法。如果使用合适的抗球蛋白血清(AGS),可通过抗球蛋白试验检测红细胞结合的补体。1971年,AGS的联邦标准受到批评,因为血库中常规使用的所谓广谱AGS被证明常常缺乏抗补体反应性。在随后的几年里,商业试剂在其抗补体成分的数量和特异性方面发生了变化。关于检测红细胞结合补体的真正重要性、应检测的补体特定片段以及似乎正在发生的非特异性反应的原因,引发了大量争议,尤其是随着利用低离子强度介质的新技术的使用日益增加。当单特异性抗IgG和抗C3在商业上可用时,关于诊断检测的争议得以解决,因为可以使用这些试剂而非广谱试剂进行直接抗球蛋白检测。仍存在两个主要问题:仅通过AGS的抗补体成分可检测到的同种抗体有多罕见?此类抗体的临床意义有多大?我们为期3年的研究结果表明,此类抗体(通常为抗基德抗体)在检测的血清中出现的发生率为1/8000。通过51Cr存活研究确定,其中一些抗体似乎能够缩短输注红细胞的寿命;一些抗体显示出可忽略不计的细胞破坏。由此类抗体引起的严重输血反应似乎不太可能发生。各个实验室将不得不权衡错过一些可能具有临床意义的补体依赖性抗体的风险与在自己实验室中使用含抗补体的AGS时遇到的非特异性增加之间的利弊。